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Much of embryonic stem cell biology has focused on transcriptional expression and regulation of genes that could mediate
its unique potential in self-renewal or pluripotency. In alignment with our present understanding on the genetic, protein, and
epigenetic factors that may direct cell fate, we present a short overview of the often overlooked contribution of alternative splice
variants to regulatory diversity. Progressing beyond the limitations of a ﬁxed genomic sequence, alternative splicing oﬀers an
additional layer of complexity to produce protein variants that may diﬀer in function and localization that can direct embryonic
stem cells to speciﬁc diﬀerentiation pathways. In light of the number of variants that can be produced at key ES cell genes alone, it
is challenging to consider how much more multifaceted transcriptional regulation truly is, and if this can be captured more fully
in future works.
1.Introduction
Embryonic stem cells (ESC or ES cells) are unique in their
abilitytoself-renew anddiﬀerentiateintospecializedlineages
representative of the three germ layers of an organism [1, 2].
Firstisolatedfromtheinnercellmass(ICM)ofamouseblas-
tocyst and subsequently in other species including human
[3], ES cells have provided insight into the fundamental
workings of otherwise inaccessible early developmental
stages. Because of the pluripotent nature of ESCs, their
potentialtoregeneratespeciﬁccelltypesisalsooftherapeutic
interest. In this respect, strides have been made with the dis-
coveryofproteinfactors thatwere ableto reprogramsomatic
cells into induced pluripotent stem cells (iPS cells) types that
bearmuch similarity toES cells[4, 5]. These reprogramming
studies together with work in ES cells have provided a vast
amount of insight into the pathways, mechanisms, and key
transcription factors involved in pluripotency. In addition
to transcriptional regulation, epigenetic mechanisms such
as chromatin modiﬁcations are now known to aid in the
activation/repression of developmental stage-speciﬁc genes
[6–9]. Reasonably, much of our present understanding of
ES cells has and will continue to arrive through comparative
studies of pluripotent cells to its diﬀerentiated counterparts,
thoughthesecomparisonsrequirefurtherreﬁnementinlight
of the multiple mechanisms and subtle diﬀerences in protein
complexes used in transcriptional regulation. Less widely
understood are the complementary mechanisms that reﬁne
the transcriptional proﬁle of ES cells, going beyond bulk
gene expression levels to look at the transcript variants and
alternative splicing (AS) that occurs at each gene.
More than 74% of human genes are known to undergo
alternative splicing [10, 11], a phenomenon that can result
in a combination of exons and/or untranslated 5  and 3 
regions (UTRs) that diﬀer from the canonical transcript.
Alternatively spliced products can have implications on
protein translation and RNA regulation [12], and aberrant
splicing is responsible for up to 15% of human genetic
disease caused by point mutations [13]. Correctly spliced,
alternative transcripts can increase the diversity of the
proteome through multiple splicing permutations, in a
manner that does not require a concomitant increase in gene
sequence.
Mouse and human ES cells share many similarities in-
cluding their dependence on key ES cell transcription factors
Oct4, Sox2, and Nanog for pluripotency [14–17], existence2 Stem Cells International
of “bivalent” chromatin marks that repress diﬀerentiation-
speciﬁc genes [18] and importance of Polycomb repres-
sor complexes in transcriptional repression [19]. However,
there are still discrepancies in the signaling pathways and
requirements for speciﬁc transcription factors or micro-
RNAs between mouse and human ES cells, the most
well-documented being that of the LIF/Jak-STAT pathway
signaling required for mouse but not human ES cells [20–
22]. In somatic cell reprogramming, a related set of factors
were found to be necessary for the generation of iPS cells.
While OCT4/Oct4 and SOX2/Sox2 were deemed necessary
for both mouse and human ES cells, additional mouse
factors originally required were Klf4 and c-Myc, whereas
the combination included NANOG and LIN28 in the case
of human ES cells [4, 5]. Plausibly, the prevalence, yet
underestimated impact of AS can serve to ﬁne-tune our
understanding of these species-speciﬁc diﬀerences, seen in
the light of the increased functional dimensions presented by
alternative transcripts.
In this paper, we highlight works related to alternative
splicing of key ES cell transcription factors. Because of the
paucity of AS variant data in ES cells, AS ﬁndings of these
factors in other developmental stages may also give insights
into the previously unexplored potential of these factors
in ES cells. This paper also demonstrates the importance
of examining splice variants despite their apparently subtle
sequence diﬀerences.
2.FunctionalImplicationsof
AlternativeSplicing
Through expressed sequence tag (EST) databases for mul-
tiple tissues and species, a large percentage of mammalian
genes (35–60%) were found to be alternatively spliced, by
alignment of these EST sequences to the cDNA reference
[23–25]. Though AS can occur anywhere across the tran-
scribed sequence, the majority of splicing occurs within the
coding region and can serve to increase the repertoire of
proteinsthat may be utilized in the cell [24, 26, 27]. While an
average of 2–5 AS transcripts are produced for each human
gene involved in AS [12], an extreme example demonstrates
the vast complexity allowed by AS; the Drosophila gene
Dscam generates a potential 38000 isoforms, separated by
developmental time and space [28].
Through the inclusion or exclusion of exons, protein
domains are altered. This can result in changes to binding
aﬃnities, catalytic activity, stability, localization, or even
posttranslational modiﬁcations [12].
Yet not all exon changes result in a new protein—some
result in the degradation of the mRNA instead. Nonsense-
mediated decay (NMD) of the mRNA occurs if a stop codon
is encountered at a distance more than 50 base pairs from
the 3  most splice junction, due to the accumulation of
NMD-associated Upf proteins at the 3  end that are not
removed by ribosomes as they traverse the mRNA sequence
[29, 30]. While these unproductive splice products are
unstable and not well understood, they are not uncommon.
Approximately 30% of alternative exons can introduce
frameshifts and stop codonsinto mRNAsequences, resulting
in a substantial amount of what is perceived as ineﬃcient
transcription [26, 31, 32]. Surprisingly, a phylogenetic study
of unproductive splice variants among primate species using
the DNApolymerase POLB gene,suggests that theseoccur at
varying frequencies among primates and are largely not con-
served, yet the extent of AS variants found correlate closely
with life expectancy, as well as age at ﬁrst reproduction [33].
Through a mechanism as yet unknown, these noncoding
protein splice forms may serve to regulate transcription,
and its levels may also be tuned to reﬂect the amount of
transcriptional control required [34, 35].
The means of AS resulting in alternative promoter usage
at the 5  and 3  UTRs are also not well understood. However,
a recent study of AS in mouse ES cells found that 12%
of genes that they examined for alternative exon usage
were mapped to alternative promoter sites [36]. Given the
function of the 5  region in transcriptional initiation, and
the poly(A) tract in the 3  end for mRNA stability, it is likely
that the use of alternative UTRs can alter the half-time of
an mRNA strand, and by extension, the amount of protein
production from a functional sequence [37, 38].
3.EvolutionaryImpact ofAlternativeSplicing
While genome-wide comparisons between human and
mouse demonstrate high-sequence conservation (∼90%) at
canonical exons of orthologous genes [39, 40], only about
25% of alternative exons were conserved. However, when
such AS exons were identiﬁed in an EST database of one
species, the corresponding exon was likely to be found
in the other species as well [40]. The authors attributed
the inclusion of a particular exon in an EST database as
indicative of a minimum expression level and found this
congruent with a ﬁnding that ancient conserved regions
correlated with more highly expressed genes [41]. It appears
that the ∼75% remainder of alternative nonconserved exons
are expressed at lower levels and segregate in a tissue-speciﬁc
manner in the species of origin, suggesting that these exons
arose after divergence from a common ancestor. The large
proportion of alternative exons with such features empha-
sizes the signiﬁcance of AS in promoting genetic variation
and possibly, speciation along with increasing organismal
complexity. Extending this to the variation oﬀered by AS
transcripts between for tissue speciﬁcity, a separate study
comparing mouse ES to hematopoietic stem cells found that
∼30% of splice variants were unique to the mouse ES cell
proﬁle, although the functionality of these variants remains
to be seen [42]. In line with the widely held view that
strongly conserved sequences are indicative of core functions
[43], ubiquitously expressed genes such as heterogeneous
nuclear ribonucleoproteins (hnRNPs) show little AS and
are located in ultraconserved regions (deﬁned as 200 base
pairs or greater of sequence with 100% identity between
human, mouse, and rat) [44, 45]. In contrast, tissue-speciﬁc
genes are likely to exhibit a larger number of AS variants
with little cross-species homology [42] and face much less
selection pressure against the insertion of Alu and other
repeat elements that can lead to sequence “exonisation” that
is permissive for species adaptation [46, 47].Stem Cells International 3
4.AlternativeTranscriptsCanDirect
ESCell Differentiation
4.1. OCT4. In both mouse and human, the OCT4/Oct4
protein is a well-described transcription factor containing
a POU domain that is able to bind a consensus octamer
sequence on DNA [48–50]. Belonging to a group of closely
relatedproteinsoftheOctfamily,OCT4isrelatedtomultiple
pseudogenes, derived from earlier retrotransposition events
into other chromosomes [51–54], as well as AS transcripts
arising directly from the Oct4/Pou5f1 locus [55, 56]. While
OCT4 pseudogenes are expressed in human hematopoietic
stem cells, it is uncertain if these pseudogenes are involved
in ES cells [53, 54]. However, alternative splicing of OCT4 is
evidentin EScells, where OCT4is most highly expressed [15,
48]. The most commonly described transcript is OCT4A,
which is translated into a full-length nuclear-localized OCT4
protein with an N- and C-terminal transactivation domain
separated by a POU DNA-binding domain [48]. Interest-
ingly, the primary shorter transcript, OCT4B, still contains
the same downstream sequence as OCT4A,a l b e i tw i t ha
shorter N-terminal domain that results from a skipped exon
1, but an extended 5  end of exon 2 [55, 56]. Though a
putative nuclear localization signal appears to be retained in
the translated OCT4B protein, it is cytoplasmically located,
in contrast to OCT4A [57].
Recently,anovelthirdtranscript,OCT4B1,wasidentiﬁed
as an ES cell-speciﬁc transcript of OCT4 and considered as
a possible stemness marker, given its signiﬁcant correlation
with NANOG expression in ES and diﬀerentiated cell lines
[56, 58]. While it is still uncertain if OCT4B1 functions pri-
marily as a transcript, or is translated into protein products,
preliminary evidence from multiple groups suggests that
OCT4B1 can be spliced into the same products as OCT4B,
all of which are cytoplasmically located [59, 60].
Furthering the diversity of output from a single locus,
OCT4 not only undergoes AS of mRNA transcripts, but goes
astepfurtherwithdiﬀerenttranslationsfrom asinglemature
mRNA form. Unusually, OCT4B and OCT4B1 mRNA both
contain 2 possible start codons, as well as an internal
ribosomal entry site (IRES) formed in part by the extended
5  end of exon 2 in OCT4B/B1 [55, 56, 61, 62]. This results
in proteins of 265, 190, and 165 amino acids (a.a.) from
OCT4B/B1 although it cannot be excluded that the 164 a.a.
long version is also translated from OCT4A,w h i c ha l s o
contains the downstream in-frame ATG codon in the 3  end
of exon 2. Structurally, the shorter OCT4 variants produced
do not contain an N-terminal transactivation domain, but
more importantly, lack the POU-S portion of the complete
POU domain [50, 63]. Functionally, it appears that OCT4A
and OCT4B variants may serve diﬀerently,since they localize
to diﬀerent cellular regions. OCT4A is found in the nucleus
and is responsible for the well-known activities of OCT4 in
ES cell self-renewal and pluripotency [64–66]. Conversely,
the full OCT4B isoform (or OCT4B-265) containing an N-
terminal transactivation domain was not able to reside in
the nucleus, nor bind to the consensus OCT4-binding site
on DNA, due to the altered conﬁguration of the N terminal
[64]. The role of OCT4B-265 in ES cells is therefore unclear,
since its diﬀerent intracellular localization precludes it from
acting as a negative regulator of OCT4A activity. A recent
study that analyzed changes to OCT4B1 transcript levels in
a gastric cancer cell line however, points to a likely role
for OCT4B1 as an antiapoptotic factor, since cells deprived
of OCT4B1 take on a giant cell morphology or undergo
apoptosisdirectly[60].InEScells,theprevalenceofOCT4B1
may also serve to manage the rapid cell cycling characteristic
of this proliferative cell type.
Interestingly, a mainly cytoplasmic pyruvate kinase,
Pkm2, has previously been described as an Oct4 interactor
[67] and may well be one of many Oct4B partners. Pkm2,
itself one of two alternative transcripts from the Pkm gene, is
theprimary transcriptatearlyembryonicstages[68]andwas
s h o w nt ob i n dt ot h eP O Ud o m a i no fO c t 4[ 67]. As the large
bodyofproteininteractiondatamaynotdistinguishbetween
Oct4 isoforms as baits, these data sets should be more
carefully examined for clues that suggest functionality for
OCT4B-265/Oct4B in the cytoplasm. Still, this cytoplasmic
Oct4 variant might just make it into the nucleus after all—
Kpna2, a protein involved in nuclear import was found to
bind to the Oct4 POU domain [69]. While all Oct4 protein
variants containanuclearlocalizationsignal,thisisnecessary
but not suﬃcient for actual nuclear localization [57]. With
the possibility of Oct4B transferred to a nuclear locale, albeit
at lower levels than in the cytoplasm, this could serve as a
self-generated negative feedback loop for the sequestration
of active Oct4A, through its heterodimerization with Oct4B.
The shorter OCT4B-190 and OCT4B-164 proteins are
not typicallyexpressed in ES cells, yet an increase in OCT4B-
190 was observed on heat shock of human ES cells, and
presumed to take on a protective role against apoptosis
[64], thereby highlighting an additional means by which
alternative transcripts function in developmental time and
function, though directed from the same locus.
Correspondingly, there is evidence that a number of
Oct4 splice variants are also found in mice, although no
present ﬁndings support the presence of a mouse homolog
to OCT4B1 [70]. Intriguingly this may be attributed in part
to the increasing evidence that suggests the nonequivalence
of human and mouse ES cells. Because of the diﬀerences in
growth factors and trophectoderm diﬀerentiation potential
of these two cell types, it is believed that human ES cells
are representative of a later epiblast stage of the developing
blastocyst than mouse ES cells [71–73]. As such, it is of
note that the lack of Oct4B1 in mouse ES cells might
demonstrate the narrowly deﬁned window of function for
OCT4B1 in human ES cells, as supported by its possible
role as a stemness marker [58]. Species-speciﬁc diﬀerences
in alternative splicing may also be a contributing factor,
suggesting that it is prescient to more carefully consider the
model systems and likelihood of alternative splice variants in
future studies.
4.2. Sall4. SALL4/Sall4 is a known ES cell-speciﬁc transcrip-
tion factor that interacts with OCT4 and Nanog and also
regulates stem cell pluripotency [74, 75]. In both mouse
and human, SALL4/Sall4 exist as two splice isoforms, Sall4a
and Sall4b that diﬀer by the inclusion or exclusion of part4 Stem Cells International
of exon 2 and results in a diﬀerent number of zinc ﬁnger
domains [76, 77]. Sall4 −/− mice fail to developan inner cell
mass (ICM), demonstrating the essentialness of one or both
isoforms in early embryonic development [74, 78].
While most otherstudieshave not distinguished between
isoforms, SALL4 mutations that aﬀect both isoforms are
implicated in the human Duane-Radial Ray syndrome and
acute myeloid leukemia (AML) [76, 79, 80]. Interestingly,
a transgenic mouse with human SALL4B recapitulated the
features of AML, suggesting that the truncated isoform is
suﬃcient to initiate disease.
Chromatin immunoprecipitation experiments for Sall4a
and Sall4b were informative for target genes of each of
these isoforms in mouse ES cells. In line with evidence
that hetero- or homodimerization of isoforms are both
possible, Sall4a/b show shared as well as distinct targets
in ES cells [77]. Shared targets were enriched for genes
involved in developmental processes and organ morpho-
genesis including the essential ES cell factors Oct4, Nanog
and Sox2, and Sall4a alone was targeted to a speciﬁc niche
of genes involved in olfaction and sensing [77]. However,
Sall4b was targeted to a larger group of genes, enriched for
transcription and gene expression. In conjunction, Sall4a/b
and Sall4b target genes alike were found with activating
chromatin marks (H3K4me3 and H3K36me3), whereas the
repressive H3K27me3 was enriched at target genes of Sall4a
[77]. In the transgenic SALL4B mouse with AML, SALL4B
expression was most evident in the initiating cancer stem
cell population, but not in the chronic disease cells [76].
Sall4b is also required for proper ICM development and
the maintenance of pluripotency [77, 81]. Through these
animal models, it is evident that the normal contribution
of this shorter isoform in development is to perpetuate self-
renewal in the ICM, and in aberrant development to sustain
a tumor initiating population of stem cells. Conversely,
the longer Sall4a isoform appears to regulate transcription
of diﬀerentiation speciﬁc genes, with bivalent chromatin
marks representing active or poised genes, present only at
loci that were cobound by other pluripotency factors such
as Oct4 [77]. A separate Sall4a/b ChIP demonstrated that
Sall4a/b binding was evident at 27% of known genes with
bivalent domains—a subset of these would include Sall4a-
only binding [18, 82].
Given the conservation of exons and alternative exons
between human and mouse, it is likely that both Sall4
isoforms are also highly conserved across other species.
Certainly the discovery of Sall4 through its homology to the
Drosophila spalt gene [74, 83] suggests its ancestral function
in organogenesis and sensory developmenthas been retained
in mammals, though this has been expanded in vertebrates
through the existence of multiple Sall family genes. While
exon exclusion in evolution occurs at <20% frequency in a
representative human gene set, it is interesting to observe
that the truncation of Exon 2 in Sall4b might have conferred
additionalcapabilitiestoSall4bfortranscriptional regulation
and its essential role in early development, in addition to
its conserved function in cell fate diﬀerentiation with Sall4a.
Despite these diﬀerences in the target genes of Sall4 brought
a b o u tb ya ne x o nt r u n c a t i o nt h a tr e s u l t e di nt h el o s sb u tn o t
ablation of all zinc ﬁnger domains, it is evident that subtle
changes to domain structure through alternative splicing is
able to directly impact protein function.
4.3. Tcf3. Tcf3 is a more recently described transcription
factor that forms part of the core regulatory network
present in ES cells [84–86]. As a transcriptional repressor
and the eﬀective end of the Wnt pathway, Tcf3 is able
to translate extracellular stimuli into a directive for tran-
scription through its binding to beta catenin. Genome-
wide analysis of Tcf3-binding sites identiﬁed its frequent co-
occupancy with some transcription factors that promulgate
self-renewal, namely, Oct4 and Nanog [84–86]. Through
this, both transcriptional activator(s) and repressor(s) are
locked in a close counter-balancing relationship that can
more sensitively regulate genes according to its cell fate
requirements. While the repressive activity of human TCF3
can be attenuated through itsphosphorylation [87],the gene
itself also undergoes AS. Available in 2 known variants, the
shorter Tcf3 (Tcf3(s)) lacks 14 a.a. present in the Groucho-
binding domain of its longer twin, Tcf3(l), though both are
expressed in mouse ES cells [36, 88, 89]. Through variant-
speciﬁc knockdowns of Tcf3, Salomonis et al. categorized
the response of 34 genes anticipated as Tcf3 target genes
as deﬁned by the available literature and looked to see if
their responses diﬀered. Sharing much similarity in domain
structure,bothTcf3variantsshowed overlapsingenetargets.
However, despite the apparently small 14 a.a. change, it
appears that Tcf3(s) and Tcf3(l) can also regulate mutually
exclusive sets of genes associated with diﬀerent downstream
pathways. While Tcf3(s) target genes were involved with
lineage diﬀerentiation, Tcf3(l) targets were more directed
towards cardiac and neural development. Clearly, AS can
increase the dimensionality of a protein’s function, while
still retaining its original purpose. Though comparisons of
beta-catenin binding to each of the Tcf3 variants has not
been described, it is very probable that both variants are
still responsive to beta catenin, since such interactions in a
domain separate from the aﬀected Groucho binding region
[90, 91].
Intriguingly, a recent study derived rat and human-
induced pluripotent stem cells that better resembled the
characteristics of mouse ES cells, including an ability to
contribute to rodent chimera models when introduced into
preimplantation embryos [92]. This involved the use of a
GSKβ inhibitor in the culture media, suggesting a strong
role for Tcf3, as part of the Wnt pathway, in regulating
pluripotency. It is plausible that the splice variants of Tcf3
observed in mouse ES cells facilitate the interconversion of
ES cells between diﬀerent “metastable” levelsof pluripotency
that ES cells are able to adopt, depending upon the available
ES cell factors [93].
5.Conclusion
Amplifying the complexity involved in decoding a gene into
a functional RNA or protein product, alternative splicing of
mRNAs occurs as a post-transcriptional regulatory process
that adds to the repertoire of known mechanisms forStem Cells International 5
organismal complexity. Through weak associations of the
mRNA with generic splicing factors, and possibly tissue-
speciﬁc splicing factors, a newly transcribed mRNA may be
transformed into a variety of protein and RNA products
that diﬀer in domain content, structure, and functional
value, depending upon the tissue of interest. Although gene
expression studies often seek to derive tissue-speciﬁc gene
expression proﬁles as a hallmark of each tissue, these studies
may not fully consider the implications of sequentially sim-
ilar but alternative transcripts whose individual expression
levels may not be resolved.
In this paper, we have considered the possible functional
implications of alternative splicing. As a post-transcriptional
regulatory mechanism, this can result in the inclusion or
exclusion of amino acid residues that can aﬀect protein
function. Because of the large number of ways in which
protein function may be regulated, disruptions can occur
through alternate posttranslational modiﬁcations, domain
content and binding site aﬃnities among others. RNA sta-
bility and regulation may precede or precludethe translation
of such a protein, especially through the introduction of
new promoter or translation start sites. Powerfully, AS
is observed through evolution and ﬁrst understood as a
means of increasing signal nodes and complexity despite the
relative similarity of DNA content between species of recent
divergence. While approximately 3/4 of all known genes
undergoAS,onlyathirdoftheseareestimatedtoshowcross-
species conservation. A study that considered the extent of
ASforasingle genebetween primatespecies suggeststhat the
frequency of such events is not conserved and instead may
correlate with life expectancy. While such correlations may
b em o r ec a s ea p p r o p r i a t et h a np r e s c r i p t i v ef o rt h ed i v e r s e
spectrum of known genes, it is interesting to consider how
transcript variety can have seemingly profound implications
on a species’ life cycle and the extent of an individual’s
environmental interactions. Additional studies demonstrate
that tissue-speciﬁc genes are subject to AS more often than
ubiquitously expressed “housekeeping genes”. In view of the
common developmental pathways shared between mam-
mals, embryonic stem cell biology has been instrumental in
providing insight into early developmental stages. Here, we
highlight 3 key ES cell transcription factors in human and
mouse that are essential for self-renewal and also show that
these factors undergo AS. While transcription factors such
as Oct4 are generally perceived to be expressed speciﬁcally
in the ICM, and to a lesser extent in primordial germ cells
ortheirin vitro equivalents,itis increasingly evidentthatour
previousnotionsofwhatconstitutes“expression”needstobe
more clearly distinguished, and that low levels of alternative
transcripts may be present in alternative cell types, but
remainunknown. Thesetranscripts canservetodiscriminate
one species from the next. Although the minority of AS
products are conserved between species, such products are
often associated with biologically important, core pathways
[43].In this paper, a number of these AS variants appear to
show such behavior, in association with their essential role
in ES cell renewal. At this point, much research in ES cell
biology has not delved signiﬁcantly to consider the impact
of alternative transcripts in modulating or expanding the
function of key ES cell factors. We anticipate that future
studies that examine the possibility of splice variants in more
detail might bring forth new evidence to distinguish ES cell
mechanisms and species diﬀerences more clearly.
Abbreviations
ESC/ES Cells: Embryonic Stem Cells
ICM: Inner Cell Mass
iPS Cells: Induced Pluripotent Stem Cells
UTR: Untranslated Region
AS: Alternative Splicing
ChIP: Chromatin Immunoprecipitation
miRNA: Micro-RNAs
NMD: Nonsense mediated decay.
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